$47m · Other round · Healthtech · Oxford, UK
Oxford-based Sensible Biotechnologies has secured $47m in combined financing to advance its cell-based mRNA design and manufacturing platform. The company's 6 October announcement says the package includes a Series A led by Oxford Science Enterprises and up to $20m in non-dilutive funding from the Slovak government and the European Union. New investors OTB Ventures and In-Q-Tel joined existing backers including Recode Ventures, Isomer Capital, Y Combinator, Backed VC, Kaya VC, Civilization Ventures and BlueYard Capital.
The $47m figure covers the combined package, rather than a standalone $47m equity round. The disclosed materials do not break out the Series A amount separately from the rest of the package beyond identifying up to $20m as non-dilutive support.
Cell-based production moves the bottleneck upstream
Most therapeutic mRNA is made through in-vitro transcription, a cell-free process. Sensible is taking a different route: its VECTOR platform combines computational sequence design, automated high-throughput screening and engineered eukaryotic cells that manufacture naturally modified mRNA. Its PromPT technology is designed to capture and protect the molecule inside the cell before purification. Sensible says external evaluations found no detectable double-stranded RNA contamination in tested material, alongside lower cytokine activation and higher protein expression than synthetic mRNA in human immune-cell assays; those are company-reported preclinical results, not clinical evidence.
The commercial bet is that design and manufacturing should be developed as one loop. For pharmaceutical partners, a sequence that performs well in an assay is only useful if it can also be produced reproducibly, purified and transferred into a clinical-grade process. Oxford Science Enterprises' Joel Schoppig framed manufacturing as part of medicine design from the start, rather than a downstream service. If Sensible can make that integration repeatable, the platform could reduce hand-offs between discovery and process development while giving partners a clearer path from candidate screening to supply.
Scaling from discovery to clinical-grade supply
The financing will fund further development of VECTOR, expansion of AI-enabled design and screening, and clinical-grade manufacturing capacity. Sensible's operating footprint mirrors that progression: its Oxford site focuses on discovery and advanced R&D, Bratislava on process development, and Šarišské Michalany in Slovakia on scale-up and cGMP manufacturing. The company has also established a strategic partnership with Sartorius to support clinical-grade scale-up, while its cell-based circular-RNA work has appeared in Nature Biotechnology and Cell Chemical Biology.
That makes the next milestone operational as much as scientific. Sensible must translate promising assay data into consistent production, quality controls and processes that can meet clinical requirements across different mRNA modalities. The mix of venture capital and public funding gives it resources for both platform development and physical manufacturing infrastructure, but the value of the package will ultimately depend on whether pharmaceutical partnerships progress into clinical programmes.
